Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Positive and negative predictive values

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Positive and negative predictive values. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-001711-85 Sponsor Protocol Number: PTF202 Start Date*: 2022-03-10
    Sponsor Name:PentixaPharm GmbH
    Full Title: A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphom...
    Medical condition: Central nervous system (CNS) lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DK (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000597-29 Sponsor Protocol Number: 2017-02-CHRMT Start Date*: 2021-06-02
    Sponsor Name:Centre Hospitalier Régional Metz-Thionville
    Full Title: Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
    Medical condition: mite allergenic rhinitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002898-26 Sponsor Protocol Number: CHBX2020/49 Start Date*: 2022-07-01
    Sponsor Name:CHU DE BORDEAUX
    Full Title: Contribution of PET/CT with Gallium 68 citrate (68Ga-PET/CT) for the diagnosis of prosthetic valve infective endocarditis
    Medical condition: Prosthetic valve infective endocarditis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003416-30 Sponsor Protocol Number: 12175 Start Date*: 2020-12-17
    Sponsor Name:Erasmus University Medical Center
    Full Title: Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging
    Medical condition: Squamous Cell Carcinoma of the Oral Cavity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003474-45 Sponsor Protocol Number: 74742 Start Date*: 2023-02-17
    Sponsor Name:Erasmus University Medical Center
    Full Title: The STELLAR trial: Fluorescence-guided surgery in laryngeal- and hypopharyngeal cancer: a feasibility trial
    Medical condition: Squamous cell carcinoma of the larynx and hypoharynx
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003397-33 Sponsor Protocol Number: IRST185.02 Start Date*: 2015-10-08
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: 68Ga-PSMA HBED-PET/CT in the evaluation of the biochemical relapse in patients with a history of prostate cancer radically treated.
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004108-44 Sponsor Protocol Number: PREMETHEP Start Date*: 2016-02-11
    Sponsor Name:Centre Georges-François Leclerc
    Full Title: PREMETHEP : Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an early predictive factor of overall survival in patients with advanced h...
    Medical condition: Hepatocellular carcinoma (HCC) is the 3rd cause of death by cancer. For patients with inoperable advanced HCC, systemic therapy with Sorafenib (Nexavar®) is the only therapeutic with proven surviva...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004159-19 Sponsor Protocol Number: 2018-00938 Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Basel
    Full Title: Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus - the CARGOx Study
    Medical condition: Polyuria-polydipsia syndrome (PPS) is divided into the three main entities central (complete or partial) diabetes insipidus (DI), nephrogenic DI and primary polydipsia (PP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004937-29 Sponsor Protocol Number: NL55621.029.15 Start Date*: 2016-06-14
    Sponsor Name:VU University Medical Center
    Full Title: Towards early identification of response to CABAZItaxel in patients with metastatic castration-resistant prostate cancer: potential of 18F-Choline PET-CT (CABAZIPET).
    Medical condition: Metastatic castration-resistant prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002585-33 Sponsor Protocol Number: PETAL Start Date*: 2023-01-19
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT)
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002773-21 Sponsor Protocol Number: 89Zr-TLX250-003 Start Date*: 2019-04-10
    Sponsor Name:TELIX International Pty Ltd
    Full Title: A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal ce...
    Medical condition: Patients with an indeterminate renal mass (IRM) detected on contrast-enhanced abdominal MR imaging or equivalent standard of care imaging, clinically suspicious for renal cell carcinoma and schedul...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001463-75 Sponsor Protocol Number: ICO-2019-04 Start Date*: 2020-02-03
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Pilot Feasibility Study: Inflammation and presence of M2 macrophages explorations with[18F]-DPA-714 PET/CT in Triple Negative breast cancers
    Medical condition: Patients with Triple Negative Breast Cancer prior to surgical treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002968-27 Sponsor Protocol Number: INTERMEDIATE-01 Start Date*: 2020-02-18
    Sponsor Name:Centre François Baclesse
    Full Title: Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration (3.7 GBq I131 after rhTSH) versus decision o...
    Medical condition: Differentiated thyroid cancer - subgroup of patients with intermediate risk of postoperative residual disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004332-11 Sponsor Protocol Number: P.64Cu.002.02 Start Date*: 2018-03-28
    Sponsor Name:A.C.O.M. -ADVANCED CENTER ONCOLOGY MACERATA -S.R.L.
    Full Title: Use of 64CuCl2 PET/CT Imaging in the selection of patients with prostate cancer in biochemical relapse after prostatectomy, to be successfully treated with salvage radiotherapy on the prostatic bed
    Medical condition: cancer on the prostatic bed
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005664-88 Sponsor Protocol Number: HB996 Start Date*: 2006-12-08
    Sponsor Name:University of Oxford
    Full Title: Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A ...
    Medical condition: Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003905-31 Sponsor Protocol Number: RF-2021-12372278 Start Date*: 2023-07-14
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer
    Medical condition: Patients with clinical suspicion of clinically relevant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000123-12 Sponsor Protocol Number: 2020110469 Start Date*: 2021-06-22
    Sponsor Name:Odense University Hospital
    Full Title: PRISMA-PET – Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging.
    Medical condition: Newly diagnosed prostate cancer, PET/CT scan used to stage newly diagnosed prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005064-15 Sponsor Protocol Number: M14DPD Start Date*: 2015-02-12
    Sponsor Name:Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-ALV)
    Full Title: Safety, feasibility and cost-effectiveness of genotype-directed individualized dosing of fluoropyrimidines
    Medical condition: Types of cancer for which capecitabine and 5-fluorouracil are authorized, this includes colorectal cancer, gastric cancer and locally advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002000-41 Sponsor Protocol Number: IRST185.07 Start Date*: 2019-11-20
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Experimental study to evaluate the impact of 18F-PSMA PET / CT in the management of patients with prostate cancer.
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029002 Neoplasm of the prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002526-23 Sponsor Protocol Number: 68GaPET-Meningioma-2013 Start Date*: 2014-02-12
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Impact of 68Ga-DOTAOTC PET for diagnosis of newly diagnosed or recurrent meningiomas
    Medical condition: Based on the finding that meningiomas express somatostatin-receptor 2 (SSTR2), PET imaging with SSTR ligands like 68Ga-DOTATOC has been proposed as a more specific method. Currently, the role of SS...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 11:05:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA